Dante Labs commits to ending Rare Disease Odysseys globally through Stripe2be: a patient-centric whole genome based solution tailored for rare disease patients
• Stripe2be uses an unbiased approach to Whole Genome Sequencing (WGS) for rare diseases: combining the information submitted from both personal patient records and statements, and using the Dante Labs proprietary WGS test and Immensa CE-IVD, ISO13485 Software.
• Dante Labs provides affordable WGS based solutions to tens of thousands of rare disease patients worldwide, from the Marshall Islands to Brazil, from the UK to Australia.
• Dante Labs works and welcomes collaborations with rare disease advocacy groups.
• 8,000 rare and ultra-rare diseases affect 400 million people in the world. 75% of these patients are children; 30% of whom die before the age of 5-years.
